Rituximab & Combination Chemotherapy Followed by Transplantation in Relapsed or Refractory Non-Hodgkin's Lymphoma

Inclusion Criteria: * Diagnosis of CD20-positive B-cell non-Hodgkin's lymphoma * Transplantation candidate * Primary induction failure * Chemotherapy refractory disease * Received at least 3 prior chemotherapy regimens or diagnosis of mantle cell lymphoma * Age 19 and over * Performance status: WHO 0-2 * Life expectancy at least 6 months * Absolute neutrophil count at least 1,000/mm3 (unless due to lymphomatous involvement of the marrow) * Platelet count more than 50,000/mm3 (unless due to lymphomatous involvement of the marrow) * Hemoglobin more than 9.0 g/dL (unless due to lymphomatous involvement of the marrow) * Fertile patients must use effective contraception * Concurrent non-steroidal hormones for non-lymphoma-related conditions (e.g., insulin for diabetes) allowed Exclusion Criteria: * No other concurrent chemotherapy * No concurrent corticosteroids except for transient control or prevention of nausea or vomiting * No concurrent external beam radiotherapy during transplantation therapy * No other concurrent antitumoral or investigational agents * No history of T-cell lymphoma * No relapse or progression after rituximab therapy within 3 months before transplantation * No serious disease or condition that would preclude study * Not pregnant or nursing/negative pregnancy test